Atrasentan
From Wikipedia, the free encyclopedia
 |
|
|
Atrasentan
|
|
| Systematic (IUPAC) name | |
| (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C29H38N2O6 |
| Mol. mass | 510.621 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Atrasentan is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called endothelin-1 protein receptor antagonists.
[edit] External links
- Atrasentan entry in the public domain NCI Dictionary of Cancer Terms
This article includes text from the U.S. National Cancer Institute's public domain Dictionary of Cancer Terms
 |
This oncology article is a stub. You can help Wikipedia by expanding it. |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
